significant improvement in glucose tolerance alone, when the results were compared with those from diabetics not on any form of treatment.
Thereafter nine of these subjects (five high-insulin secretors and four low-or normal-insulin secretors) continued on the dietary therapy alone, and eleven of the remaining fourteen subjects (six high-insulin secretors and five low-or normal-insulin secretors) continued on the low-calorie diet with the addition of fenfluramine, and their glucose tolerance and insulin secretion were measured again after a further 10 weeks. The remaining three subjects were no longer studied. The nine subjects continuing on the diet alone showed maintenance of the improvement in glucose tolerance achieved during the first 10-week period with no significant change in insulin secretion. The eleven subjects placed on fenfluramine in addition to the diet also showed maintenance of the improvement in glucose tolerance achieved during the first 10-week period with a significant decrease in insulin secretion in the six high-insulin secreting subjects and no significant change in insulin secretion in the five lowor normal-secretors.
Introduction
For many years it has been known that the glucose tolerance of some obese diabetics was considerably improved after a period on a low carbohydrate diet (Himsworth, 1949) . Karam et al. (1965) demonstrated an improvement in glucose tolerance and reduction ofinsulin secretion to normal in an 18-yearold obese diabetic female subject who reduced from 20% overweight to 5% underweight on a diet of 800 calories/day for 9 weeks. Rudnick & Taylor (1965) showed an improvement in glucose tolerance and increase in insulin secretion in seven mild diabetic subjects with widely differing degrees of obesity after 2 months' treatment with a lowcarbohydrate diet. Hales, Stein & Stowers (1966) studied the glucose tolerance of a group of very obese diabetic subjects before and after a period on a very low carbohydrate diet, and showed that in those patients with a deterioration of glucose tolerance after the diet, plasma insulin concentrations increased, whereas patients whose glucose tolerance was improved on the diet showed decreased insulin concentrations. McKiddie & Buchanan (1969) Fenfluramine is a non-addictive amphetamine derivative with appetite-depressing activity (Foxwell, Funderburk & Ward, 1969) , and is used along with dietary control in the treatment of obesity since it produces greater loss in weight than other anorexigenic amphetamines (Craddock, 1969 ). An indication that fenfluramine might have a further action in addition to its appetite-depressing property arose when von Herold, Kemper & Opitz (1965) recorded that the drug brought about a reduction in the blood glucose concentration in rats. Subsequently, using the forearm preparation of Butterfield & Holling (1959) , several workers have shown that intraarterial infusion of the drug increases the uptake of glucose and oxygen by muscle independently of alteration in blood flow (Whichelow et al., 1971; Turtle, Burgess & Bauckham, 1971) . Because of this effect on carbohydrate metabolism the effect of fenfluramine was studied as an aid to dietary treatment in maturity-onset obese diabetics. Kipnis (1968) Morley, Dawson & Marks (1968) , the coefficient of variation being 4-6% at a blood glucose concentration of 106 mg/100 ml. Plasma immunoreactive insulin was measured in duplicate on each specimen by the method of Hales & Randle (1963) using radioactive iodinated insulin and Oxoid membrane filters supplied by the Radiochemical Centre at Amersham. The pre-precipitated antibody and standard human insulin were supplied by Burroughs Wellcome. The standard deviation of the assay method was: (a) ±2-92 LU/ml for 115 duplicate determinations of 0-49 /,U/ml, (b) ±6-51 lU/ml for 64 of 50-99 ,uU/ml and (c) ±7-25~u U/ml for 55 of 100-200 AU/ml. If a plasma insulin concentration >200 lU/ml was found, the sample was diluted to < 200 /LU/ml, and then re-assayed. Otherwise all specimens from one subject were determined in the same batch. Categorization of patients studied and statistical methods of comparison
The area under the glucose-tolerance test curve from 0 to 2j hr was measured as an index of glucose tolerance (Burns et al., 1965) ; a decrease in the area represents an improvement in this parameter. Insulin secretion was represented by the area under the plasma insulin curve from 0 to 2j hr (Perley & Kipnis, 1965) . The range of insulin secretion obtained from the normal controls was 1200-5003 puU-min/ml so that patients producing quantities of insulin less than 1200 pjU-min/ml, between 1200 and 5003 b'U-min/ml and greater than 5003 pU-min/ml are referred to as low-, normal-and high-secretors respectively.
Of the eleven obese subjects placed on fenfluramine in addition to the diet for the second 10-week period, six were high-insulin secretors and five low-or normal-insulin secretors on first presentation. Of the nine subjects continuing on the diet alone for the second 10-week period five were high secretors and four low or normal secretors.
To obtain an assessment of the reproducibility of measurement of the glucose tolerance, the difference between the two indices from each of the eleven healthy normal individuals on whom the oral glucose-tolerance test was repeated, was expressed as a percentage of the mean of the two indices. Similarly for the patients, the difference between the glucose-tolerance indices of two consecutive tests was expressed as a percentage of the mean of the two indices. Likewise, percentages were calculated for the differences in consecutive insulin secretions.
Knowing the reproducibility of measurement of the glucose tolerance and insulin secretion, the probability that the changes in these parameters were due to random variation in their estimation was calculated by statistically comparing the percentages from the patients with those from the normal subjects by the non-parametric Mann-Whitney U-test as described by Sokal & Rohlf (1969) .
Similar changes occurring in the percentages in glucose tolerance and insulin secretion were calculated for the diabetics not adhering to any form of treatment. The changes in the subjects adhering to diet could be compared with the latter as controls by the Mann-Whitney U-test.
The following controls were used to assess the significance of the changes in the patients on diet plus fenfluramine. They were compared: (i) with the reproducibility of the measurements on the eleven healthy normal subjects; (ii) with the changes in those patients who were not adhering to the diet and who were not on any other form of therapy; (iii) with the changes in the same category of diabetic continuing on diet alone for the same 10-week period; (iv) with the changes in the same subjects on diet alone during the first 10-week period.
The average time in minutes of occurrence of the peak of the insulin curve in the diabetics on first presentation was compared with that of the normal controls. A comparison was also made with the time of occurrence of the peak after the various forms of treatment.
The range of insulin secretion in the first i and 1 hr of the glucose-tolerance test was compared in the high-insulin secreting individuals with the normal-or low-insulin secreting individuals to see whether in the initial stages of the glucose-tolerance test there was a significant difference between the two groups in the amount of insulin secreted.
Results
Figures 1 and 2 show on a semi-logarithmic scale the glucose tolerance and insulin secretion of (a) twenty-one normal subjects, (b) eleven normal subjects on whom a repeat test was performed, (c) seventeen obese maturity-onset diabetics, baseline and after two successive 10-week periods on various types of therapy. The results are not shown from the six low-or normal-secretors on diet alone for the first 10-week period, four of whom were studied for the second period of 10 weeks continuing on diet alone. The results are shown from the one highinsulin secretor studied only for the first 10-week period. Flenfluramine, low-calorie diet and obese maturity-onset diabetics Tables 1 and 2 demonstrate the statistical significance of the effect of dietary therapy alone and dietplus-fenfluramine respectively on the glucose tolerance and insulin secretion of obese maturity-onset diabetics, when the results are compared with the various controls. Table 3 shows the average time in minutes of occurrence of the peak of the insulin curve in (a) diabetics after various forms of therapy, and (b) in normal controls and compares them with that in diabetics on first presentation, i.e. untreated. Change in glucose tolerance of obese 'high- Change in insulin secretion of the same obese ---NS 'low-or normal-secretors' on diet alone for first 10 weeks *NS, not significant. improvement in glucose tolerance (0.10>P> 005) in the 'low-or normal-secretors'. When the changes in glucose tolerance and insulin secretion during the second 10-week period on diet were compared with the changes in those parameters in the same subjects during the first 10-week period on diet, there was no significant difference (Table 1) , i.e. the significant improvement in glucose tolerance and the lack of significant change in the insulin secretion after the first 10-week period were still maintained after the second 10-week period with no additional improvement or deterioration in glucose tolerance or significant change in insulin secretion having occurred. However, the small number of subjects available for study on diet alone for the second 10-week period should be borne in mind in interpreting these results. Rudnick & Taylor (1965) also showed a maintenance of the improvement in glucose tolerance in their diabetic subjects on dietary therapy during the second 2-month period of their study. (Beckett & Brookes, 1967) . Thus, the changes detected in the present subjects would appear to be associated mainly with a long-term effect rather than direct drug action.
Hence, treatment of 'high-insulin secreting' diabetics with low-calorie diet alone brings about an improvement in glucose tolerance with no significant effect on the insulin secretion. When fenfluramine is added to the dietary treatment, the improvement in glucose tolerance is maintained, and is associated with a significant decrease in insulin secretion, i.e. less insulin is needed to maintain the same level of glucose tolerance. This is in agreement with the finding of increased glucose assimilation in peripheral tissue in the presence of fenfluramine Whichelow et al., 1971) . However, apart from a direct action, the results in this present paper indicate that there is a long-term effect of the drug on the handling of glucose by the body. Kipnis (1968) suggested that the metabolic abnormality in diabetes mellitus is a delayed insulin secretory response to glucose. Table 3 indicates that neither diet alone nor diet-plus-fenfluramine has any significant effect on this aspect of the diabetic state. Table 4 illustrates that the division of obese maturity-onset diabetics on first presentation into 'high-insulin' and 'low-or normal-insulin secreting' on the basis of the overall 2k-hr insulin secretion during an OGTT is justified in that the 30-min and 60-min secretions are also significantly different between the two categories.
Thus, in 'high-insulin secreting' obese diabetics, as in obese non-diabetics (Dykes, 1973) , the administration of fenfluramine with diet after a period on diet alone is highly effective in producing a significant decrease in the quantity of insulin secreted. It remains to be seen if this is an important therapeutic effect in view of the suggested association between high plasma insulin concentrations and the development of atheroma (Stout & Vallance-Owen, 1969) .
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